EXACT Sciences Corporation (NASDAQ:EXAS) today announced that the New England Journal of Medicine has published the results of the Company’s multi-center study, the first-ever study of its stool-based DNA test, PreGen-Plus, versus the most widely used fecal occult blood test, Hemoccult(R) II. Researchers found that the Company’s non-invasive stool-based DNA test for colorectal cancer was four-times more sensitive than the fecal occult blood test (FOBT), the only other entirely non-invasive colorectal cancer screening test available today. The stool-based DNA test was able to detect all stages of colorectal cancer in an average-risk, asymptomatic population, including the earliest-stage, most curable colorectal cancers.
